A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa

Table 1 Model inputs: rates of severe nocturnal hypoglycaemia per 100 person years [15]

Insulin	Base	Range	Proportion nocturnal hypoglycaemia
NPH once daily	50.65	30.17–68.61	0.2215
Detemir once daily	40.81	30.17–57.21	0.2000
Glargine-U100	49.67	30.17–65.70	0.1569
Glargine-U300	50.26	30.17–91.82	0.1417
Degludec	45.68	30.17–57.17	0.1081

ISSN: 1478-7547